Published in Cancer Res on December 01, 1994
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A (1997) 2.55
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer (2009) 1.78
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol (2008) 1.56
Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31
BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol (1999) 1.29
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J Cell Biol (2013) 1.12
BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol (2003) 1.12
Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci (2011) 1.05
Common BRCA1 variants and transcriptional activation. Am J Hum Genet (1997) 1.05
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol (2011) 1.02
Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. J Cancer Res Clin Oncol (2010) 1.02
BRCA1, BRCA2 and their possible function in DNA damage response. Br J Cancer (1999) 0.96
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet (1996) 0.96
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. Br J Cancer (2001) 0.95
Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Res (2000) 0.94
Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. Int J Cancer (2011) 0.84
Mapping and conformational characterization of the DNA-binding region of the breast cancer susceptibility protein BRCA1. Biochem J (2006) 0.82
DNA damage response mediated through BRCA1. Cancer Res Treat (2004) 0.81
BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development. PLoS One (2014) 0.78
Recessive oncogenes: current status. Pathol Oncol Res (1995) 0.77
Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci (2016) 0.75
Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell (1994) 9.73
All ras proteins are polyisoprenylated but only some are palmitoylated. Cell (1989) 9.68
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (1994) 6.16
A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell (1990) 6.08
Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 5.95
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J (1994) 4.37
The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature (1988) 4.33
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J (1995) 4.17
Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J (1992) 4.00
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature (1992) 3.78
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature (1998) 3.67
A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J (1991) 3.64
Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol (1998) 3.58
Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J (1989) 3.51
Normal p21N-ras couples bombesin and other growth factor receptors to inositol phosphate production. Nature (1986) 3.41
EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr Biol (1994) 3.06
Dynamic fatty acylation of p21N-ras. EMBO J (1987) 2.99
Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A (1988) 2.99
Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature (1985) 2.90
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol (1995) 2.82
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J (1999) 2.79
Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J (2001) 2.66
Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J (1995) 2.51
Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem (1997) 2.47
Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol (1998) 2.33
rho family GTPase activating proteins p190, bcr and rhoGAP show distinct specificities in vitro and in vivo. EMBO J (1993) 2.31
Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res (1991) 2.30
DNA in medicine. Oncogenes. Lancet (1984) 2.28
Post-translational modifications of p21rho proteins. J Biol Chem (1992) 2.17
Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J (1991) 2.09
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst (1977) 2.07
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science (1998) 2.06
Mesoderm induction in Xenopus caused by activation of MAP kinase. Nature (1995) 1.86
Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1. J Biol Chem (1993) 1.79
Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol (1999) 1.77
Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv (1996) 1.74
A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J Biol Chem (1993) 1.74
A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J (1994) 1.68
A transforming gene present in human sarcoma cell lines. Nature (1982) 1.67
Biochemical and biological properties of the human N-ras p21 protein. Mol Cell Biol (1987) 1.65
Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. EMBO J (1984) 1.56
Scrape-loading of Swiss 3T3 cells with ras protein rapidly activates protein kinase C in the absence of phosphoinositide hydrolysis. Oncogene (1989) 1.50
The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhanced signalling and reduced sensitivity to dual specificity phosphatase action. FEBS Lett (1994) 1.47
Transformation and stimulation of DNA synthesis in NIH-3T3 cells are a titratable function of normal p21N-ras expression. EMBO J (1986) 1.46
The influence of the MAPK pathway on T cell lineage commitment. Immunity (1997) 1.43
Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol (1997) 1.41
Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene (1999) 1.41
CLINICAL EXPERIENCES WITH PERCAIN, A NEW LOCAL ANAESTHETIC. Br Med J (1930) 1.40
Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature (1984) 1.40
Cost savings controversy. J Ophthalmic Nurs Technol (1991) 1.39
The urease ELISA for H-Y antibody. A cautionary tale. J Immunol Methods (1990) 1.38
Maintenance of long-term potentiation in rat dentate gyrus requires protein synthesis but not messenger RNA synthesis immediately post-tetanization. Neuroscience (1989) 1.37
Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol (2001) 1.37
Mutant but not normal p21 ras elevates inositol phospholipid breakdown in two different cell systems. Oncogene (1988) 1.37
Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol (1999) 1.37
p21H-ras-induced morphological transformation and increases in c-myc expression are independent of functional protein kinase C. EMBO J (1989) 1.36
A study of ras gene mutations in colonic adenomas from familial polyposis coli patients. Oncogene (1988) 1.35
A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res (1986) 1.33
p21ras couples the T cell antigen receptor to extracellular signal-regulated kinase 2 in T lymphocytes. J Exp Med (1993) 1.32
Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol Cell Biol (1993) 1.31
Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. Proc Natl Acad Sci U S A (1986) 1.29
Stimulation of phosphatidylcholine hydrolysis, diacylglycerol release, and arachidonic acid production by oncogenic ras is a consequence of protein kinase C activation. J Biol Chem (1989) 1.26
Inheritance of proliferative breast disease in breast cancer kindreds. Science (1990) 1.24
Activation of the Ral and phosphatidylinositol 3' kinase signaling pathways by the ras-related protein TC21. Mol Cell Biol (2001) 1.23
Signal transduction. Hot lips and phosphorylation of protein kinases. Nature (1994) 1.23
Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. J Biol Chem (1995) 1.19
Synthesis of ribosomal RNA in synkaryons and heterokaryons formed between human and rodent cells. J Cell Sci (1975) 1.18
Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res (1997) 1.17
Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells. Proc Natl Acad Sci U S A (1986) 1.16
Down-regulation of the POU transcription factor SCIP is an early event in oligodendrocyte differentiation in vitro. Development (1992) 1.15
Activation of the Raf/MAP kinase cascade by the Ras-related protein TC21 is required for the TC21-mediated transformation of NIH 3T3 cells. EMBO J (1999) 1.11
Integrin beta1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. Br J Cancer (2005) 1.10
MAP kinase regulation--the oncogene connection. Trends Cell Biol (1992) 1.09
Cell block preparation as an adjunctive diagnostic technique in ThinPrep monolayer preparations: a case report. Diagn Cytopathol (2001) 1.07
Three different activated ras genes in mouse tumours; evidence for oncogene activation during progression of a mouse lymphoma. EMBO J (1984) 1.07
Cell signalling. Raf gets it together. Nature (1996) 1.06
Tyrosine 763 of the murine granulocyte colony-stimulating factor receptor mediates Ras-dependent activation of the JNK/SAPK mitogen-activated protein kinase pathway. Mol Cell Biol (1997) 1.05
Targeting of oncoproteins to membranes by fatty acylation. J Cell Sci Suppl (1989) 1.02
Localisation of the human N-ras oncogene to chromosome 1cen - p21 by in situ hybridisation. EMBO J (1983) 1.02
Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. J Biol Chem (1999) 1.01
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene (2010) 1.00
gamma-Glutamyltranspeptidase and the ras-induced transformation of a rat liver cell line. Cancer Res (1986) 1.00
Complementation of byr1 in fission yeast by mammalian MAP kinase kinase requires coexpression of Raf kinase. Nature (1993) 0.99
The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure (1995) 0.99
Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol (1997) 0.97
The threonine residues in MAP kinase kinase 1 phosphorylated by MAP kinase in vitro are also phosphorylated in nerve growth factor-stimulated rat phaeochromocytoma (PC12) cells. FEBS Lett (1994) 0.97
Ice-active proteins from the Antarctic nematode Panagrolaimus davidi. Cryobiology (2005) 0.96
Interleukin 1 and tumour necrosis factor activate the mitogen-activated protein (MAP) kinase kinase in cultured cells. FEBS Lett (1993) 0.96
Specific cytogenetic abnormalities and k-ras mutation in two new human colorectal-adenoma-derived cell lines. Int J Cancer (1992) 0.95
The role of MAP kinase kinase in interleukin-3 stimulation of proliferation. Blood (1996) 0.93
A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem (1999) 0.93
Cold tolerance of an Antarctic nematode that survives intracellular freezing: comparisons with other nematode species. J Comp Physiol B (2007) 0.93
Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J Biol Chem (1995) 0.93